Stock Yards Bank & Trust Co. Trims Stock Holdings in AbbVie Inc. $ABBV

Stock Yards Bank & Trust Co. lowered its stake in AbbVie Inc. (NYSE:ABBV) by 5.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,876 shares of the company’s stock after selling 3,045 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in AbbVie were worth $12,587,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in ABBV. Chelsea Counsel Co. bought a new stake in AbbVie during the 3rd quarter worth approximately $26,000. Litman Gregory Wealth Management LLC purchased a new position in AbbVie during the fourth quarter valued at approximately $28,000. Westend Capital Management LLC bought a new position in shares of AbbVie in the fourth quarter worth approximately $29,000. Imprint Wealth LLC boosted its position in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the period. Finally, Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the third quarter worth $31,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 3 data for its venetoclax-based CLL treatment at the EHA 2026 Congress, reinforcing the drug’s safety and efficacy profile and supporting confidence in its hematology franchise.
• Positive Sentiment: AbbVie and Genmab’s lymphoma program met its primary endpoint in a Phase 3 trial, raising the odds of label expansion and a larger commercial opportunity for Epkinly.
• Positive Sentiment: News that AbbVie is acquiring Apogee Therapeutics has been viewed as a growth-supportive move, signaling continued pipeline expansion through M&A.
• Positive Sentiment: AbbVie also highlighted Aquipta’s efficacy for acute migraine following EU approval, adding another potential growth driver in its neuroscience portfolio.
• Neutral Sentiment: Analysts at Erste Group trimmed their FY2026 and FY2027 EPS estimates slightly, but the reductions were small and remained near consensus, so the impact looks limited.
• Negative Sentiment: US lawmakers opened an investigation into AbbVie and other drugmakers over clinical trials conducted in China, which could create headline risk and raise compliance concerns.

Analysts Set New Price Targets

ABBV has been the topic of several recent analyst reports. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a research report on Thursday, April 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Canaccord Genuity Group raised their price target on AbbVie from $265.00 to $273.00 and gave the company a “buy” rating in a report on Tuesday, June 23rd. Wells Fargo & Company set a $260.00 price objective on AbbVie in a research report on Monday, June 22nd. Finally, Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $253.81.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $251.07 on Thursday. The firm has a fifty day moving average price of $217.86 and a 200 day moving average price of $219.76. AbbVie Inc. has a fifty-two week low of $184.63 and a fifty-two week high of $255.99. The firm has a market cap of $443.59 billion, a price-to-earnings ratio of 123.68, a P/E/G ratio of 0.83 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.46 EPS. As a group, research analysts predict that AbbVie Inc. will post 14.28 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.